[Deresinated naphthalan in the treatment of psoriatic arthritis]

The paper presents pathogenetic validation for introduction of naphthalane oil as a therapeutic modality in psoriatic arthritis. The criteria of the inflammation activity are specified. As a result of deresinified naphthalane treatment, 43 psoriatic patients exhibited positive trends in clinical and laboratory manifestations of the inflammation, reduced intensity of the disease, declined articular and skin syndromes. The response persisted for 6 months.